Latest research on Celecoxib

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.

Latest findings

Comparatively, the potency of 50 μg Tat-SOD was almost equivalent to that of 10 mg Celecoxib. [source, 2016]
Celecoxib as a positive control only showed a minor primary inflammatory characteristic (Fig. 3e, f; yellow arrows). [source, 2016]
Our results showed that topical administration of Tat-SOD inhibited SNP-induced COX-2 expression as well as did Celecoxib. [source, 2016]
Celecoxib, a selective COX-2 inhibitor, is widely used to treat rheumatoid arthritis, psoriatic arthritis, adenomatous polyposis, and osteoarthritis [49, 50]. [source, 2016]
Compared to Celecoxib, Tat-SOD exhibited a similar potency in dose-dependently inhibiting COX-2 expression through a different mechanism. [source, 2016]
mice with inhibitors that block both COX1 and COX2 (Indomethacin) and COX2 alone (Celecoxib) abrogates mortality induced by the lethal dose of TsV. [source, 2016]
Similar results were observed in C57BL/6 mice injected with a lethal dose of TsV and treated with Indomethacin, Celecoxib or an EP2 antagonist, AH6809. [source, 2016]
Although ∼50–70% of C57BL/6 mice died after administration of 180 μg kg−1 TsV, Indomethacin, Celecoxib and EP2 antagonist treatment decreased mortality, PGE2 and IL-1β production and neutrophil infiltration in the lungs (Fig. 4b–d). [source, 2016]
In a specific experiment, the mice were either treated or not treated with MK886 (5-LO inhibitor, 5 mg kg−1 i.p., in 200 μl of 1% alcohol in water)64, Indomethacin (COX1/2 inhibitor, 2 mg kg−1 i.p. in 200 μl of Tris[hydroxymethyl]aminomethane-HCl; TRIS-HCl, pH 8.2)65, SC-560 (selective COX1 inhibitor, 3 mg kg−1 i.p., in 200 μl of PBS, Sigma-Aldrich)66, Celecoxib (COX2 inhibitor, 5 mg kg−1 i.p., in 200 μl of water)64 or EP2 antagonist (AH6809, 5 mg kg−1 i.p., in 200 μl of PBS, Cayman Chemical)67. [source, 2016]
The others drugs (SC-560, Celecoxib, and EP2 antagonist) or vehicles were administered 1 day and again 1 h before the i.p. injection of lethal dose of TsV (180 μg kg−1). [source, 2016]